<DOC>
	<DOC>NCT01840449</DOC>
	<brief_summary>The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.</brief_summary>
	<brief_title>Somatuline Predictive Factors in Acromegaly and NET</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Written informed consent (also mandatory in case of retrospective documentation of subject data) Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG The subject has already been included in this study Participation in an interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>